Piper Jaffray Cuts Anadys (ANDS) to Neutral
Tweet
Share
E-mailGet Alerts ANDS Hot Sheet
Price: $3.70 --0%
Rating Summary:
0 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 18 | New: 4
Rating Summary:
0 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 18 | New: 4
Join SI Premium – FREE
Piper Jaffray downgraded shares of Anadys Pharmaceuticals (NASDAQ: ANDS) from Overweight to Neutral Monday morning. The firm's target was raised from $3 to $3.70.
Shares of Anadys are up more than 250 percent this morning amid a buyout from Roche.
For more ratings news on Anadys Pharmaceuticals click here and for the rating history of Anadys Pharmaceuticals click here.
Shares of Anadys are up more than 250 percent this morning amid a buyout from Roche.
For more ratings news on Anadys Pharmaceuticals click here and for the rating history of Anadys Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Sylvamo Corp. (SLVM) to Neutral
- BofA Securities Downgrades O-I Glass Inc. (OI) to Underperform
- Kepler Cheuvreux Downgrades BPER Banca (BPE:IM) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
